ACAngela Chan

Angela Chan

*This is an algorithmically generated author record based on publicly available information.

Angela Chan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease

    by Conor J Howard, Nathan S Abell, Robert R Warneford-Thomson, Eden Mahdavi, Alan L Su, Carmen Resnick, Nabil Mohammed, Erin M Thompson, Emily R Holzinger, Katrina Catalano, et al.

    Tyrosine Kinase 2 (TYK2) is a genetically defined target for autoimmune disease, with first-generation inhibitors showing clinical success in some but not all associated indications. A deeper understanding of TYK2 structure-function, protein-ligand interactions, and the impact of human variants could inform next-generation therapeutics. Here, we applied Deep Mutational Scanning (DMS) to assess >23,000 amino acid substitutions across two TYK2 functions: IFN-α signaling and protein abundance. This enabled high-resolution structure-function mapping and the identification of novel allosteric sites. By coupling DMS with inhibitor treatment, we uncovered variants that modulate compound potency. We also show that human variants – both common and rare – that are protective against autoimmune phenotypes reduce TYK2 protein abundance. Together, these findings demonstrate that DMS can prospectively reveal novel druggable sites, clarify structure-activity relationships (SAR), and highlight TYK2 degradation as a potential therapeutic strategy in autoimmunity.

  • Open Access

    Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease

    by Conor J. Howard, Nathan S. Abell, Robert R. Warneford-Thomson, Eden Mahdavi, Alan L. Su, Carmen Resnick, Nabil Mohammed, Erin M. Thompson, Emily R. Holzinger, Katrina Catalano, et al.

    Tyrosine Kinase 2 (TYK2) is a genetically defined target for autoimmune disease, with first-generation inhibitors showing clinical success in some but not all associated indications. A deeper understanding of TYK2 structure-function, protein-ligand interactions, and the impact of human variants could inform next-generation therapeutics. Here, we applied Deep Mutational Scanning (DMS) to assess >23,000 amino acid substitutions across two TYK2 functions: IFN-α signaling and protein abundance. This enabled high-resolution structure-function mapping and the identification of novel allosteric sites. By coupling DMS with inhibitor treatment, we uncovered variants that modulate compound potency. We also show that human variants – both common and rare – that are protective against autoimmune phenotypes reduce TYK2 protein abundance. Together, these findings demonstrate that DMS can prospectively reveal novel druggable sites, clarify structure-activity relationships (SAR), and highlight TYK2 degradation as a potential therapeutic strategy in autoimmunity.